Anatumomab Usage And Synthesis

Uses

Anatumomab mafenatox (ABR-214936) is a 73 KDa recombinant protein to recognize the tumor-associated antigen 5T4, which is widely expressing in malignancy. Anatumomab mafenatox is between a modified form of SEA and a murine Fab. The main side effects of Anatumomab mafenatox are reported to include fever, low blood pressure, pain, nausea and drowsiness[1].

References

[1] Shaw DM, et al. A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74. DOI:10.1038/sj.bjc.6603567

Anatumomab(1370261-50-9)Related Product Information

• Research Grade Inotuzumabc (DHD38502)
• Crenezumab
• Berlimatoxumab
• Merpentan
• Vopratelimab
• Lodapolimab
• Gremubamab
• Begelomab
• Bezlotoxumab
• Livmoniplimab